459833-33-1

Usage

Explanation

This is the chemical name of the compound, which is also known as lornoxicam.

Explanation

Lornoxicam belongs to a class of drugs called NSAIDs, which are used to reduce inflammation, pain, and fever.

Explanation

Lornoxicam exhibits properties that help reduce inflammation, relieve pain, and lower fever.

Explanation

Lornoxicam is commonly used to alleviate pain and inflammation in various conditions, including arthritis and menstrual cramps.

Explanation

Lornoxicam works by inhibiting the production of prostaglandins, which are responsible for causing pain and inflammation in the body.

Explanation

Lornoxicam can be found in various forms, such as tablets, capsules, and injections, for administration to patients.

Explanation

It is important to obtain and use lornoxicam under the guidance of a healthcare professional to ensure proper dosage and minimize potential risks.

Explanation

Although lornoxicam is effective in relieving pain and inflammation, it may cause adverse effects such as gastrointestinal bleeding, kidney dysfunction, and cardiovascular complications if not used with caution.

Classification

Nonsteroidal anti-inflammatory drug (NSAID)

Properties

Anti-inflammatory, analgesic, and antipyretic

Common uses

Relief of pain and inflammation associated with conditions such as arthritis and menstrual cramps

Mechanism of action

Inhibition of prostaglandin production

Available forms

Tablets, capsules, and injections

Prescription

Typically prescribed under the supervision of a healthcare professional

Potential adverse effects

Gastrointestinal bleeding, kidney dysfunction, and cardiovascular complications

Upstream product

• 459833-32-0 Methyl 2-isobutoxy-5-(methylsulfonyl)benzoate 
• 101371-44-2 methyl 2-hydroxy-5-(methylsulfonyl)benzoate 

Relevant academic research and scientific papers

Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors

Regulation of glycine transporter 1 (GlyT1) activity is a currently investigated strategy in drug discovery for schizophrenia. This study developed a series of new 4-benzoylpiperidine derivatives as GlyT1 inhibitors by bioisosteric replacement and mimicking of the pyridine ring of RG1678. Among the 4-benzoylpiperidine derivatives, 23q showed an IC50 of 30 nM. Preliminary optimization of the blood-brain barrier penetration led to the discovery of 3-(piperidin-4-yl)benzo[d]isoxazole derivatives. Both series showed good selectivity over GlyT2, D1, D2, D3, 5-HT1A and 5-HT2A receptors. Moreover, behavioral testing showed 23q (40 mg kg-1, intragastric) can inhibit the hyperlocomotion induced by acute treatment of phencyclidine, and improve the impaired negative and cognitive symptoms in chronic phencyclidine-induced C57BL/6J mice. An interesting finding showed that 3-(piperidin-4-yl)benzo[d]isoxazole was a privileged scaffold of atypical antipsychotic agents but exhibited high selectivity and potency as a GlyT1 inhibitor.

PHENYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-METHANONES AND THE USE THEREOF AS MEDICAMENT

The present inventions relates to substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones of general formula (I) wherein R1, R2, R3, R4, R5 and R6 are as herein described or salts thereof, preferably pharmaceutically acceptable salts thereof. The invention further relates to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various conditions such as conditions concerning positive and negative symptoms of schizophrenia as well as cognitive impairments associated with schizophrenia, Alzheimers Disease and other neurological and psychiatric disorders. The compounds of the invention show glycine transporter-1 (GlyT 1) inhibiting properties.

Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament

Substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones which are glycine transporter-1 (GlyT1) inhibitors. These are useful for the treatment of schizophrenia, Alzheimer's Disease and other neurological and psychiatric disorders.

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors

Screening of the Roche compound library led to the identification of the benzoylpiperazine 7 as a structurally novel GlyT1 inhibitor. The SAR which was developed in this series resulted in the discovery of highly potent compounds displaying excellent sele

Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups

The present invention relates to compounds of the general formula I wherein R1 is the group and R2, R′, R″, R3, R4, R5, R6, R7, X1, X1′, X2, and

[4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS

The present invention relates to compounds of the general formula (I) wherein R1 is-OR1’,-SR1’ or is a heterocycloalkyl group; R1’ is lower alkyl, lower alkyl substituted by halogen or is -(CH2)n

Heterocyclic-substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.

Bi- and tricyclic substituted phenyl methanones

The present invention relates to compounds of the general formula I and R1, R′,; R″, R2, R3, R4, R5, R6, R7, m and n are as defined in the specification, and to pharmaceutically

BENZOYL-PIPERAZINE DERIVATIVES

The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.